Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR (RIFAMAB)
Primary Purpose
Prosthetic Infection
Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Rifabutin
Rifampicin
Sponsored by
About this trial
This is an interventional treatment trial for Prosthetic Infection
Eligibility Criteria
Inclusion Criteria:
- Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy initiation and retention of prothesis (DAIR strategy)
Infected with at least one of the following microorganisms:
- Staphylococcus aureus
- Coagulase-negative staphylococci
- Microorganisms susceptible to rifampicin and at least one other antibiotic suitable for the treatment of PJI (e.g., penicillin, fluoroquinolone, (doxy/mino)cycline, oxazolidinone, cotrimoxazole, daptomycin, glycopeptide, macrolide, fusidic acid), regardless of sensitivity to methicillin.
- Age ≥ 18 years
- At least 2 days of appropriate (i.e., covering pathogen(s) identified in the intraoperative samples) empirical agents are needed. Pre-randomization antimicrobial therapy could be: flucloxacillin, oxacillin, vancomycin, daptomycin. β-lactam plus β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except ceftazidime), carbapenems, teicoplanin, ceftaroline, ceftobiprole.
- Signed Inform consent
- Patient having the rights to French social insurance
- For women of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile and excluding oestroprogestative-based contraception, any effective contraceptive: vasectomy (for men), intrauterine device copper, feminine sterilization, condom, sexual abstinence is required. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause
Exclusion Criteria:
- Suspicion of reduce absorption of oral treatment due to abdominal disorder Known or suspected malabsorption (imperfect absorption of food material by the small intestine)
- Polymicrobial infection due to other than staphylococcus species susceptible to rifampicin
- Known or suspected allergy to rifabutin and/or rifampicin
- Diagnosis of endocarditis associated to PJI
- Renal transplant or Chronic kidney disease with an eGFR of less than 30ml/min/1.73m²
- Other Solid Organ Transplant
- Liver cirrhosis, Child-Pugh score C
- Any other concomitant infection which required a prolonged course of intravenous antibiotic therapy
- Oestroprogestative-based contraception
- Oral anticoagulant drugs
- Other drug-drug interaction that contraindicated rifampicin or rifabutin
- Porphyria
- Unable to take oral treatment
- Receive empirical postoperative antibiotic treatment by rifampicin or rifabutin prior to randomization
- Pregnancy or lactating women
- Curator or guardianship or patient placed under judicial protection
- Participation in other interventional research during the study
Sites / Locations
- CHU Amiens Picardie
- CHU Angers
- CHU BesançonRecruiting
- CHU Bordeaux
- APHP Hôpital Ambroise Paré
- CHRU BrestRecruiting
- CH de Béthune
- CHU CaenRecruiting
- CH Alpes Leman
- CHU Dijon Bourgogne
- CHU Grenoble Alpes
- CHRU LilleRecruiting
- GHICL Hôpital Saint Vincent de Paul
- CHU de LimogesRecruiting
- GHICL Hôpital Saint Philibert
- Clinique de la Sauvegarde
- Hospices Civils de Lyon
- APHM Hôpital Nord
- CHU Nice
- CH Annecy GenevoisRecruiting
- CH Cornouaille
- CHU Reims
- CHU de RennesRecruiting
- CHU Saint Etienne
- CHRU Strasbourg
- Hôpital d'instruction des armées Sainte AnneRecruiting
- Clinique Joseph Ducuing
- Clinique Médipole Garonne
- CH TourcoingRecruiting
- CHRU ToursRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
RIFAMPICIN
RIFABUTIN
Arm Description
Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
Outcomes
Primary Outcome Measures
Treatment failure
Treatment failure defined as one of following events:
The need for any further surgical procedure - i.e. implants removal, implants exchange or amputation;
And/or PJI related death;
And/or use of suppressive antibiotic therapy that was not planned before randomization
Secondary Outcome Measures
Occurrence of serious adverse events (SAEs), including death (i.e. all cause)
Proportion of patient which are free from SAEs occurrence, as defined by:
-Patients who completed the entire 12 weeks duration of antibiotic treatment planned initially and; xWho did not experience grade 3-4 adverse events, including death, regardless of the link with antibiotic therapy; xWho did not experience adverse events which led to either to:
Reduce the dosage or split the treatment to two take/day;
Or stop any component of the antibiotic treatment.
Occurrence of any adverse event that could be related to rifampicin or rifabutin
Number and rate of patients in each arm who experiences:
Liver cytolysis (>=2N for ALT AND/OR AST)
Acute Kidney failure as defined by serum creatinine increase in KDIGO
Digestive symptoms, including diarrhea
Who required a modification of antibiotic dosage during the 12 weeks' period of antibiotic treatment
Uveitis/ophthalmologic disorder
Neurological disorder
Proportion of patients from each arm who will complete the 12-week duration of rifampicin/rifabutin treatment, early termination of the planned 12 weeks' period of antibiotics
Early termination rate will be measured in each arm, as the number of patients having stopped rifampicin or rifabutin before the planned 12 weeks period over the total number of patients enrolled in the studied arm.
Adherence to antibiotics regimen
Adherence rate to medication will be measured as the number of days on which all doses were missed over the number of days of planned antibiotic therapy. Patients enrolled in the study will have to fill their pill count in a daily notebook.
Quality of life, as evaluated by EQ 5D 3L questionnaire
Quality of life, as evaluated by the use EQ 5D 3L auto-questionnaire as used in previous randomized clinical trial on bone and joint infection
Functional prognosis using Oxford questionnaire evolution according to location of PJI
Oxford Scores as used in previous randomized clinical trial on bone and joint infection
Long term efficacy of rifampicin and rifabutin treatment
Long term efficacy: treatment failure, as defined for primary outcome, at 24 months
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04672525
Brief Title
Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
Acronym
RIFAMAB
Official Title
Rifabutin Versus Rifampicin for Treatment of Staphylococcal Prosthetic Joint Infection Treated With Debridement, Antibiotics and Implant Retention (DAIR Strategy): a Multicenter Randomized, Open-label, Non-inferiority Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 8, 2021 (Actual)
Primary Completion Date
November 2026 (Anticipated)
Study Completion Date
June 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tourcoing Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prosthetic Infection
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
436 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
RIFAMPICIN
Arm Type
Active Comparator
Arm Description
Patient with staphylococcal PJI, treated with DAIR strategy, and randomized in the control group will receive rifampicin in association with another antibiotic except rifabutin, as-per recommendations for 12 weeks.
Arm Title
RIFABUTIN
Arm Type
Experimental
Arm Description
Patient with staphylococcal PJI treated with DAIR strategy, and randomized in the experimental group, will receive rifabutin in association with another antibiotic except rifampicin, as-per recommendations for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Rifabutin
Intervention Description
2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
Intervention Type
Drug
Intervention Name(s)
Rifampicin
Intervention Description
10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
Primary Outcome Measure Information:
Title
Treatment failure
Description
Treatment failure defined as one of following events:
The need for any further surgical procedure - i.e. implants removal, implants exchange or amputation;
And/or PJI related death;
And/or use of suppressive antibiotic therapy that was not planned before randomization
Time Frame
At one year
Secondary Outcome Measure Information:
Title
Occurrence of serious adverse events (SAEs), including death (i.e. all cause)
Description
Proportion of patient which are free from SAEs occurrence, as defined by:
-Patients who completed the entire 12 weeks duration of antibiotic treatment planned initially and; xWho did not experience grade 3-4 adverse events, including death, regardless of the link with antibiotic therapy; xWho did not experience adverse events which led to either to:
Reduce the dosage or split the treatment to two take/day;
Or stop any component of the antibiotic treatment.
Time Frame
At the end of 12 weeks duration of antibiotic treatment planned
Title
Occurrence of any adverse event that could be related to rifampicin or rifabutin
Description
Number and rate of patients in each arm who experiences:
Liver cytolysis (>=2N for ALT AND/OR AST)
Acute Kidney failure as defined by serum creatinine increase in KDIGO
Digestive symptoms, including diarrhea
Who required a modification of antibiotic dosage during the 12 weeks' period of antibiotic treatment
Uveitis/ophthalmologic disorder
Neurological disorder
Time Frame
At the end of 12 weeks duration of antibiotic treatment planned
Title
Proportion of patients from each arm who will complete the 12-week duration of rifampicin/rifabutin treatment, early termination of the planned 12 weeks' period of antibiotics
Description
Early termination rate will be measured in each arm, as the number of patients having stopped rifampicin or rifabutin before the planned 12 weeks period over the total number of patients enrolled in the studied arm.
Time Frame
At the end of 12 weeks duration of antibiotic treatment planned
Title
Adherence to antibiotics regimen
Description
Adherence rate to medication will be measured as the number of days on which all doses were missed over the number of days of planned antibiotic therapy. Patients enrolled in the study will have to fill their pill count in a daily notebook.
Time Frame
At the end of 12 weeks duration of antibiotic treatment planned
Title
Quality of life, as evaluated by EQ 5D 3L questionnaire
Description
Quality of life, as evaluated by the use EQ 5D 3L auto-questionnaire as used in previous randomized clinical trial on bone and joint infection
Time Frame
At the end of the study follow up, an average of 24 months
Title
Functional prognosis using Oxford questionnaire evolution according to location of PJI
Description
Oxford Scores as used in previous randomized clinical trial on bone and joint infection
Time Frame
At the end of the study follow up, an average of 24 months
Title
Long term efficacy of rifampicin and rifabutin treatment
Description
Long term efficacy: treatment failure, as defined for primary outcome, at 24 months
Time Frame
At the end of the study follow up, an average of 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hip or knee Prosthetic joint infection treated by debridement, antibiotic therapy initiation and retention of prothesis (DAIR strategy)
Infected with at least one of the following microorganisms:
Staphylococcus aureus
Coagulase-negative staphylococci
Microorganisms susceptible to rifampicin and at least one other antibiotic suitable for the treatment of PJI (e.g., penicillin, fluoroquinolone, (doxy/mino)cycline, oxazolidinone, cotrimoxazole, daptomycin, glycopeptide, macrolide, fusidic acid), regardless of sensitivity to methicillin.
Age ≥ 18 years
At least 2 days of appropriate (i.e., covering pathogen(s) identified in the intraoperative samples) empirical agents are needed. Pre-randomization antimicrobial therapy could be: flucloxacillin, oxacillin, vancomycin, daptomycin. β-lactam plus β-lactamase-inhibitors (e.g. ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except ceftazidime), carbapenems, teicoplanin, ceftaroline, ceftobiprole.
Signed Inform consent
Patient having the rights to French social insurance
For women of childbearing potential i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile and excluding oestroprogestative-based contraception, any effective contraceptive: vasectomy (for men), intrauterine device copper, feminine sterilization, condom, sexual abstinence is required. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause
Exclusion Criteria:
Suspicion of reduce absorption of oral treatment due to abdominal disorder Known or suspected malabsorption (imperfect absorption of food material by the small intestine)
Polymicrobial infection due to other than staphylococcus species susceptible to rifampicin
Known or suspected allergy to rifabutin and/or rifampicin
Diagnosis of endocarditis associated to PJI
Renal transplant or Chronic kidney disease with an eGFR of less than 30ml/min/1.73m²
Other Solid Organ Transplant
Liver cirrhosis, Child-Pugh score C
Any other concomitant infection which required a prolonged course of intravenous antibiotic therapy
Oestroprogestative-based contraception
Oral anticoagulant drugs
Other drug-drug interaction that contraindicated rifampicin or rifabutin
Porphyria
Unable to take oral treatment
Receive empirical postoperative antibiotic treatment by rifampicin or rifabutin prior to randomization
Pregnancy or lactating women
Curator or guardianship or patient placed under judicial protection
Participation in other interventional research during the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eric SENNEVILLE, MD PhD
Phone
0320694949
Email
esenneville@ch-tourcoing.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Solange TREHOUX
Phone
0320694280
Email
strehoux@ch-tourcoing.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric SENNEVILLE, Md PhD
Organizational Affiliation
CH Tourcoing
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Amiens Picardie
City
Amiens
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoit BRUNSCHWEILER
Facility Name
CHU Angers
City
Angers
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Besançon
City
Besançon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kévin BOUILLER
Facility Name
CHU Bordeaux
City
Bordeaux
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fréderic-Antoine DAUCHY
Facility Name
APHP Hôpital Ambroise Paré
City
Boulogne-Billancourt
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurélien DINH
Facility Name
CHRU Brest
City
Brest
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Severine ANSART
Facility Name
CH de Béthune
City
Béthune
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Caen
City
Caen
Country
France
Individual Site Status
Recruiting
Facility Name
CH Alpes Leman
City
Contamine-sur-Arve
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Dijon Bourgogne
City
Dijon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lionel PIROTH
Facility Name
CHU Grenoble Alpes
City
Grenoble
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Lille
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henry MIGAUD
Facility Name
GHICL Hôpital Saint Vincent de Paul
City
Lille
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU de Limoges
City
Limoges
Country
France
Individual Site Status
Recruiting
Facility Name
GHICL Hôpital Saint Philibert
City
Lomme
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Clinique de la Sauvegarde
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne-Laure BLANC
Facility Name
Hospices Civils de Lyon
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tristan FERRY
Facility Name
APHM Hôpital Nord
City
Marseille
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU Nice
City
Nice
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan COURJON
Facility Name
CH Annecy Genevois
City
Pringy
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Violaine TOLSMA
Facility Name
CH Cornouaille
City
Quimper
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lydie KHATCHATOURIAN
Facility Name
CHU Reims
City
Reims
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHU de Rennes
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cédric ARVIEUX
Facility Name
CHU Saint Etienne
City
Saint-Priest-en-Jarez
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CHRU Strasbourg
City
Strasbourg
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cécile RONDE-OUSTAU
Facility Name
Hôpital d'instruction des armées Sainte Anne
City
Toulon
Country
France
Individual Site Status
Recruiting
Facility Name
Clinique Joseph Ducuing
City
Toulouse
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Clinique Médipole Garonne
City
Toulouse
Country
France
Individual Site Status
Not yet recruiting
Facility Name
CH Tourcoing
City
Tourcoing
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eric SENNEVILLE
Facility Name
CHRU Tours
City
Tours
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louis BERNARD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
We'll reach out to this number within 24 hrs